Sprint Bioscience AB Share Price Nasdaq Stockholm
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- | - |
14/02 | Sprint Bioscience AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
14/02 | Sprint Bioscience AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Sales 2024 * | 118M 10.81M 0 902M | Sales 2025 * | 199M 18.23M 0 1.52B | Capitalization | 92.86M 8.51M 0 710M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 0.04 x |
Net cash position 2024 * | 88.2M 8.08M 0 674M | Net cash position 2025 * | - 0 - 0 | EV / Sales 2025 * | 0.47 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 47.2% |
Managers | Title | Age | Since |
---|---|---|---|
Johan Emilsson
CEO | Chief Executive Officer | 40 | 01/23/01 |
Martin Andersson
FOU | Founder | 53 | 01/09/01 |
Director of Finance/CFO | 51 | 01/11/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 68 | 01/20/01 | |
Chairman | 56 | 01/21/01 | |
Fredrik Lehmann
BRD | Director/Board Member | 48 | 01/19/01 |
1st Jan change | Capi. | |
---|---|---|
-0.94% | 104B | |
+6.11% | 97.47B | |
+5.71% | 22.25B | |
-13.38% | 21.68B | |
-9.70% | 18.2B | |
-39.98% | 17.02B | |
-10.05% | 16.36B | |
+8.44% | 14.39B | |
+39.71% | 12.37B |